PCSK9 plasma concentration is associated with epicardial adipose tissue volume and metabolic control in patients with type 1 diabetes
Por:
Sardà, H, Colom, C, Benitez, S, Carreras, G, Amigó, J, Miñambres, I, Viladés, D, Blanco-Vaca, F, Sanchez-Quesada, JL, Pérez, A
Publicada:
26 mar 2024
Resumen:
Patients with type 1 diabetes (T1D) have a greater risk of cardiovascular disease. Proconvertase subtilisin-kexin 9 (PCSK9) is involved in the atherosclerosis process. This study aimed to determine the relationship between PCSK9 levels and epicardial adipose tissue (EAT) volume and cardiometabolic variables in patients with T1D. This was an observational cross-sectional study including 73 patients with T1D. Clinical, biochemical and imaging data were collected. We divided the patients into two groups according to their glycemic control and the EAT index (iEAT) percentile. We performed a correlation analysis between the collected variables and PCSK9 levels; subsequently, we performed a multiple regression analysis with the significant parameters. The mean age was 47.6 +/- 8.5 years, 58.9% were men, and the BMI was 26.9 +/- 4.6 kg/m(2). A total of 31.5%, 49.3% and 34.2% of patients had hypertension, dyslipidemia and smoking habit, respectively. The PCSK9 concentration was 0.37 +/- 0.12 mg/L, which was greater in patients with worse glycemic control (HbA1c > 7.5%), dyslipidemia and high EAT volume (iEAT > 75th percentile). The PCSK9 concentration was positively correlated with age (r = 0.259; p = 0.027), HbA1c (r = 0.300; p = 0.011), insulin dose (r = 0.275; p = 0.020), VLDL-C level (r = 0.331; p = 0.004), TG level (r = 0.328; p = 0.005), and iEAT (r = 0.438; p < 0.001). Multiple regression analysis revealed that 25% of the PCSK9 variability was explained by iEAT and HbA1c (p < 0.05). The PCSK9 concentration is associated with metabolic syndrome parameters, poor glycemic control and increased EAT volume in patients with T1D.
Filiaciones:
Sardà, H:
Hosp Santa Creu & Sant Pau, Hosp Dos De Maig, Dept Endocrinol & Nutr, Antoni Maria Claret 167, Barcelona 08025, Spain
Univ Autonoma Barcelona, Dept Med, Bellaterra, Spain
Colom, C:
Hosp Santa Creu & Sant Pau, Hosp Dos De Maig, Dept Endocrinol & Nutr, Antoni Maria Claret 167, Barcelona 08025, Spain
Benitez, S:
Inst Recerca St Pau IR St Pau, Cardiovasc Biochem Grp, St Quinti 77-79, Barcelona 08041, Spain
CIBER Diabet & Enfermedades Metab CIBERDEM, Madrid, Spain
Carreras, G:
Hosp Santa Creu & Sant Pau, Dept Pediat, Barcelona, Spain
Univ Autonoma Barcelona, Dept Pediat Obstet & Gynecol, Bellaterra, Spain
Univ Autonoma Barcelona, Prevent Med & Publ Hlth, Bellaterra, Spain
Amigó, J:
Hosp Univ Vall dHebron, Dept Endocrinol & Nutr, Barcelona, Spain
Miñambres, I:
Hosp Santa Creu & Sant Pau, Hosp Dos De Maig, Dept Endocrinol & Nutr, Antoni Maria Claret 167, Barcelona 08025, Spain
Univ Autonoma Barcelona, Dept Med, Bellaterra, Spain
CIBER Diabet & Enfermedades Metab CIBERDEM, Madrid, Spain
Viladés, D:
Hosp Santa Creu & Sant Pau, Cardiol Dept, Cardiac Imaging Unit, Barcelona, Spain
Ctr Invest Red Enfermedades Cardiovasc CIBERCV, Madrid, Spain
Blanco-Vaca, F:
CIBER Diabet & Enfermedades Metab CIBERDEM, Madrid, Spain
Hosp Santa Creu & Sant Pau, Dept Clin Biochem, IIB St Pau, Barcelona, Spain
Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Bellaterra, Spain
Sanchez-Quesada, JL:
Inst Recerca St Pau IR St Pau, Cardiovasc Biochem Grp, St Quinti 77-79, Barcelona 08041, Spain
CIBER Diabet & Enfermedades Metab CIBERDEM, Madrid, Spain
Pérez, A:
Hosp Santa Creu & Sant Pau, Hosp Dos De Maig, Dept Endocrinol & Nutr, Antoni Maria Claret 167, Barcelona 08025, Spain
Univ Autonoma Barcelona, Dept Med, Bellaterra, Spain
CIBER Diabet & Enfermedades Metab CIBERDEM, Madrid, Spain
gold
|